作者
John A. Thompson,Bryan J. Schneider,Julie R. Brahmer,Mohammad Abu Zaid,Amaka Achufusi,Philippe Armand,Meghan Berkenstock,Bonnie L. Bermas,Tawnie Braaten,Lihua E. Budde,Saurin Chokshi,Zachary D. Crees,Marianne Davies,Changchun Deng,Yaron Gesthalter,Michael D. Jain,Prantesh Jain,Andrew Jallouk,Benjamin H. Kaffenberger,Maya Khalil,Melissa G. Lechner,Tianhong Li,Alissa Marr,Suzanne McGettigan,Jordan P. McPherson,Theresa Medina,Nisha Mohindra,Anthony J. Olszanski,Olalekan O. Oluwole,Sandip Pravin Patel,Jason Prosek,Sunil Reddy,Pankti Reid,John Ryan,Mabel Ryder,Huda Salman,Bianca Santomasso,Scott Shofer,Jeffrey A. Sosman,Yinghong Wang,Vlad G. Zaha,Stephen D. Zucker,Megan Lyons,Ajibola Awotiwon,Lisa Hang
摘要
The NCCN Guidelines for the Management of Immunotherapy-Related Toxicities are intended to provide oncology practitioners with guidance on how to manage the wide-ranging and potentially fatal toxicities that may occur with cancer immunotherapy. The guidelines address immune-related adverse events related to immune checkpoint inhibitors, CAR T-cell therapies, and lymphocyte engagers (which include T-cell–engaging bispecific antibodies). These NCCN Guidelines Insights highlight recent guideline updates pertaining to the management of emerging toxicities related to cancer immunotherapy.
不配.
个性的紫菜
Cloud
薰硝壤
爱静静
都是
寻道图强
ShowMaker
iNk
乐乐乐乐乐乐
kento
Yziii
浅尝离白
pcr163
Singularity
shinysparrow
坚强亦丝
HEIKU
小墨
好困
皖公网安备34019202002308
